This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot2: STU1 Ballot 2) based on FHIR (HL7® FHIR® Standard) v6.0.0. No current official version has been published yet. For a full list of available versions, see the Directory of published versions
{
"resourceType" : "Group",
"id" : "282882",
"meta" : {
"versionId" : "5",
"lastUpdated" : "2025-03-26T21:52:45.205Z"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"extension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-author",
"valueContactDetail" : {
"name" : "Brian S. Alper"
}
},
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/cite-as",
"valueMarkdown" : "NHANES LBXGLU Variable Definition [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 282882. Revised 2024-10-15. Available at: https://fevir.net/resources/Group/282882. Computable resource at: https://fevir.net/resources/Group/282882#json."
}
],
"url" : "https://fevir.net/resources/Group/282882",
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "urn:ietf:rfc:3986",
"value" : "https://fevir.net/FOI/282882",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"title" : "NHANES LBXGLU Variable Definition",
"status" : "active",
"publisher" : "Computable Publishing LLC",
"contact" : [
{
"telecom" : [
{
"system" : "email",
"value" : "support@computablepublishing.com"
}
]
}
],
"description" : "This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/",
"membership" : "conceptual",
"combinationMethod" : "all-of",
"characteristic" : [
{
"code" : {
"text" : "Laboratory test"
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://loinc.org",
"code" : "1558-6",
"display" : "Fasting glucose [Mass/volume] in Serum or Plasma"
}
],
"text" : "Fasting plasma glucose"
},
"exclude" : false
},
{
"code" : {
"text" : "Unit of measure"
},
"valueCodeableConcept" : {
"text" : "mg/dL"
},
"exclude" : false
},
{
"code" : {
"text" : "Method"
},
"valueCodeableConcept" : {
"text" : "Description of Laboratory Methodology - Glucose - In this enzymatic method glucose is converted to glucose-6-phosphate (G-6-P) by hexokinase in the presence of ATP, a phosphate donor. Glucose-6-phosphate dehydrogenase then converts the G-6-P to gluconate-6-P in the presence of NADP+. As the NADP+ is reduced to NADPH during this reaction, the resulting increase in absorbance at 340 nm (secondary wavelength = 700 nm) is measured. This is an endpoint reaction that is specific for glucose. Refer to the Laboratory Method Files section for a detailed description of the laboratory methods used. There were no changes to the lab site or lab method for this component in the NHANES 2017-2018 cycle. There were no changes to the lab equipment since 2015-2016. The Cobas C311 analyzer was used in 2017-2018 and 2015-2016. Refer to analytic note for changes to equipment in earlier survey cycles, which may impact analysis. Plasma Fasting Glucose Laboratory Procedure Manual (August 2020) https://wwwn.cdc.gov/nchs/data/nhanes/2017-2018/labmethods/GLU-J-MET-508.pdf"
},
"exclude" : false
}
]
}